NCT06277024招募中不适用
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Fujian Medical University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients
详细描述
Local advanced or metastatic HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histopathology or cytology that cannot be resected, and has not received systemic treatment (including HER2 inhibitors) as the primary treatment for advanced or metastatic diseases in the past.
Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients Median survival time (OS);
- Progression free survival time (PFS);
- Duration of relief (DOR); Evaluate the safety of this regimen in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma patients, including the incidence of adverse events (AE), severe adverse reactions (SAE), dose adjustment rate, and dose pause rate; Observe the changes in quality of life of patients with advanced gastric or gastroesophageal junction adenocarcinoma after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 years ≤ Age ≤ 75 years;
- •Locally advanced or metastatic HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histopathology or cytology that cannot be resected;
- •Has not received radiotherapy, chemotherapy, targeted therapy, or immunotherapy as the primary treatment option for advanced or metastatic diseases in the past; Participants with gastric or gastroesophageal junction adenocarcinoma who have previously received adjuvant or neoadjuvant chemotherapy, radiotherapy, and/or radiochemotherapy are eligible for enrollment as long as the last administration of the previous protocol occurred at least 6 months prior to randomization.
- •At least one measurable lesion #see Appendix 2#;
- •ECOG PS: 0-1 points #see Appendix 4#;
- •Estimated survival time>3 months;
- •The main organ function is normal and meets the following criteria:
- •Blood routine examination must meet the following criteria#no blood transfusion within 14 days#
- •HB ≥ 100g/L,
- •WBC ≥ 3 × 109/L
- •ANC ≥ 1.5 × 109/L,
- •PLT ≥ 100 × 109/L;
- •Biochemical examination must meet the following standards:
- •BIL<1.5 times the upper limit of normal value #ULN#,
- •ALT and AST<2.5ULN, GPT ≤ 1.5 × ULN;
- •Serum Cr ≤ 1ULN, endogenous creatinine clearance rate>60ml/min #Cockcroft Gault formula#
- •Women of childbearing age must undergo a pregnancy test #serum# within 7 days before enrollment, and the result is negative. They are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug; For males, surgical sterilization or agreement to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug should be considered; 9# Not participating in other clinical studies before and during treatment; 10# The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.
排除标准
- •If a subject meets any of the following conditions, they will not be allowed to enter this study
- •Patients with allergies or suspected allergies to research drugs or similar drugs;
- •Suffering from other malignant tumors within the past 5 years, excluding skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ;
- •Received live vaccine within 4 weeks prior to enrollment or possibly during the study period;
- •Suffering from active autoimmune diseases or having a history of autoimmune diseases within 4 weeks prior to enrollment;
- •Previously received allogeneic bone marrow transplantation or organ transplantation;
- •The patient currently has any disease or condition that affects drug absorption, or the patient is unable to take medication orally;
- •The patient currently has hypertension that cannot be controlled by medication, which is defined as: patients with hypertension who cannot be well controlled with a single antihypertensive drug treatment #systolic blood pressure ≥ 150 mmHg, diastolic blood pressure ≥ 100mmHg#; Or use two or more antihypertensive drugs to control blood pressure in patients;
- •Urinary routine indicates that urine protein is ≥ 2+, and the 24-hour urine protein volume is>1.0g;
- •The patient currently has digestive tract diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectable tumors, or other conditions determined by the researcher that may cause gastrointestinal bleeding or perforation;
- •Patients with significant evidence of bleeding tendency or medical history within the 3 months prior to enrollment #bleeding>30 mL within 3 months, vomiting blood, black stool, and rectal bleeding#, hemoptysis #fresh blood>5 mL within 4 weeks#, or thromboembolic events #including stroke events and/or transient ischemic attacks# within 12 months;
- •Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting surgery within 6 months prior to enrollment; Congestive heart failure is classified by the New York Heart Association #NYHA# as>level 2; Ventricular arrhythmia requiring medication treatment; Electrocardiogram #ECG# shows a QT interval of ≥ 480 milliseconds;
- •Active or uncontrolled severe infection #≥ CTCAE level 2 infection#;
- •Known human immunodeficiency virus #HIV# infection; Known clinically significant history of liver disease, including viral hepatitis [known carriers of hepatitis B virus #HBV# must exclude active HBV infection, i.e. HBV DNA positivity #>1 × 104 copies/mL or>2000 IU/ml#; Known hepatitis C virus infection #HCV# and HCV RNA positivity #>1 × 103 copies/mL, or other types of hepatitis or cirrhosis;
- •According to the judgment of the researchers, patients deemed unsuitable for inclusion in this study.
研究组 & 干预措施
Treatment with combination of candenizumab, lenvatinib, and SOX regimen
Experimental
干预措施: Combination of Cardonizumab with Lenvatinib and SOX regimen (Drug)
结局指标
主要结局
ORR
时间窗: 3 years
Overall Response Rate
次要结局
未报告次要终点
研究者
Chang-Ming Huang, Prof.
chief physician
Fujian Medical University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionImmunotherapy Gastroesophageal JunctionNCT06396585Fujian Cancer Hospital28
进行中（未招募）
2 期
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm StudyStomach NeoplasmsDigestive System NeoplasmsNeoplasmsDigestive System DiseasesStomach DiseasesNeoplasms by SiteNCT05602935The Second Affiliated Hospital of Fujian Medical University29
进行中（未招募）
1 期
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the BrainMetastatic Renal Cell CarcinomaBrain MetastasesNCT06132945Memorial Sloan Kettering Cancer Center2
Unknown
2 期
Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric CancerLocally Advanced Gastric CancerNCT04792515First Affiliated Hospital Xi'an Jiaotong University67
已完成
2 期
SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCCHepatocellular CarcinomaNCT03578874The University of Hong Kong15